Recently, several clinical trials have shown that immune checkpoint inhibitors targeting the PD-1/PD-L1 axis exhibit robust antitumor efficacy in multiple advanced cancers (Finn et al., 2020; Galsky et al., 2020; Gutzmer et al., 2020; Herbst et al., 2020). This evidence concerns the gene CD274 and cancer.